Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
FPR3 Biologics Sequence Review Report 2026: N-formyl peptide receptor 3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FPR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FSHR Biologics Sequence Review Report 2026: Follicle-stimulating hormone receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FSHR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FPR2 Biologics Sequence Review Report 2026: N-formyl peptide receptor 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FPR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EDNRB Biologics Sequence Review Report 2026: Endothelin receptor type B Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of EDNRB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
F2RL1 Biologics Sequence Review Report 2026: Proteinase-activated receptor 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of F2RL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCGRT Biologics Sequence Review Report 2026: IgG receptor FcRn large subunit p51 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FCGRT protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
F2R Biologics Sequence Review Report 2026: Proteinase-activated receptor 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of F2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DRD3 Biologics Sequence Review Report 2026: D(3) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DRD5 Biologics Sequence Review Report 2026: D(1B) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DRD2 Biologics Sequence Review Report 2026: D(2) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DRD4 Biologics Sequence Review Report 2026: D(4) dopamine receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DRD4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CRHR1 Biologics Sequence Review Report 2026: Corticotropin-releasing hormone receptor 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CRHR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
12
13
14
15
16
>>
1670
>